This website is intended for people living in Europe only. Healthcare professionals in Europe can visit our HCP site.

tgct awareness

WHAT ARE THE SYMPTOMS
OF TGCT?

Every person who has TGCT (also known as pigmented villonodular synovitis [PVNS]) will have a different experience of this disease. Whether you're dealing with the diffuse or nodular-type, many of the symptoms can be similar. However, it's important to remember that these symptoms can vary widely from person to person.1,2

COMMON SYMPTOMS

Pain Pain1
STIFFNESS STIFFNESS1
Limited Range of Motion LIMITED RANGE
OF MOTION1
(joint doesn't move as easily or as far as it used to)
JOINT LOCKING JOINT LOCKING1
SWELLING SWELLING1

In some cases, a person can be diagnosed with TGCT but not experience any symptoms – this is known as asymptomatic TGCT.1

Magnifier Click here to find out more about asymptomatic TGCT Chevron

LIVING WITH TGCT

A number of studies have shown the negative impact of TGCT on those living with the disease, both physically and mentally:3–5

92%

experienced pain*5

83%

experienced joint stiffness*5

85%

experienced limited range of motion*5

19%

experienced at least moderate anxiety or depression†4

TGCT HAS ALSO SHOWN TO AFFECT PROFESSIONAL AND SOCIAL LIFE:

63%

were unable to take part in sport activities*3

23%

changed job or had to retire early*5

These statistics are from international studies on the challenges of living with diffuse and nodular TGCT, as reported by patients.3–5 You can find more details about these statistics below. The symbols next to the percentages show which information they refer to.

*In this study, approximately 70% of participants with TGCT had the diffuse type and 20% had the nodular type.3,5 It is worth noting that this may not reflect real-world cases, where the diffuse form is usually less common.1,5

†This statistic is from a study in which all cases were diffuse-type TGCT.4

Magnifier Click here to learn about how TGCT is diagnosed Chevron

References:

  1. Stacchiotti S, et al. Cancer Treat Rev. 2023;112:102491.
  2. Berthnal NM, et al. Orphanet J Rare Dis. 2021;16(1):191.
  3. Mastboom MJL, et al. Interact J Med Res. 2018;7(1):e4.
  4. Lopez-Bastida J, et al. Orphanet J Rare Dis. 2021;16(1):294.
  5. Stern S, et al. Future Oncol. 2025:1–10.

DCPH-P02569 | January 2026